Insmed Incorporated (NASDAQ:INSM) Shares Bought by RWC Asset Management LLP

RWC Asset Management LLP raised its holdings in Insmed Incorporated (NASDAQ:INSM) by 13.0% during the fourth quarter, HoldingsChannel.com reports. The firm owned 3,485 shares of the biopharmaceutical company’s stock after buying an additional 401 shares during the period. RWC Asset Management LLP’s holdings in Insmed were worth $241,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. V Square Quantitative Management LLC grew its position in Insmed by 60.3% in the 4th quarter. V Square Quantitative Management LLC now owns 659 shares of the biopharmaceutical company’s stock worth $45,000 after purchasing an additional 248 shares during the last quarter. Spire Wealth Management purchased a new stake in shares of Insmed in the fourth quarter valued at $47,000. Venturi Wealth Management LLC acquired a new stake in shares of Insmed during the fourth quarter worth approximately $86,000. Quantbot Technologies LP acquired a new stake in shares of Insmed during the 3rd quarter valued at about $133,000. Finally, Blue Trust Inc. raised its holdings in shares of Insmed by 2,348.8% during the 3rd quarter. Blue Trust Inc. now owns 1,959 shares of the biopharmaceutical company’s stock valued at $131,000 after purchasing an additional 1,879 shares in the last quarter.

Insmed Trading Down 3.0 %

INSM opened at $81.06 on Monday. The firm has a market capitalization of $14.50 billion, a PE ratio of -14.50 and a beta of 1.11. Insmed Incorporated has a fifty-two week low of $21.92 and a fifty-two week high of $84.91. The company’s 50-day moving average is $74.29 and its 200 day moving average is $73.61. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. The company had revenue of $104.44 million for the quarter, compared to the consensus estimate of $102.31 million. As a group, research analysts predict that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Insider Activity at Insmed

In other news, insider Martina M.D. Flammer sold 3,344 shares of the stock in a transaction on Tuesday, January 7th. The shares were sold at an average price of $65.91, for a total value of $220,403.04. Following the transaction, the insider now owns 102,766 shares of the company’s stock, valued at $6,773,307.06. This represents a 3.15 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Orlov S. Nicole Schaeffer sold 91,140 shares of the firm’s stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now owns 97,083 shares in the company, valued at $7,766,640. The trade was a 48.42 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 532,207 shares of company stock worth $41,400,465. Corporate insiders own 4.60% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $90.00 price objective on shares of Insmed in a research note on Friday. Stifel Nicolaus dropped their price target on shares of Insmed from $97.00 to $96.00 and set a “buy” rating for the company in a research report on Friday. Truist Financial boosted their target price on shares of Insmed from $105.00 to $108.00 and gave the company a “buy” rating in a research note on Friday. JPMorgan Chase & Co. raised their price target on Insmed from $83.00 to $92.00 and gave the company an “overweight” rating in a report on Friday, February 7th. Finally, Morgan Stanley boosted their target price on shares of Insmed from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Thursday, February 6th. One analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $91.00.

Insmed Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.